RARE
What one share of Ultragenyx Pharmaceutical holds
Pharmaceutical Preparations
We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
Ultragenyx Pharmaceutical’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $7.13 |
|---|---|
| Profit | −$5.83 |
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | −$4.86 |
| Cash and investments | $1.27 |
| Book value | −$2.95 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$6.21 | $0.26 | −$4.32 | — | $11.49 |
| 2017 | $0.06 | −$7.12 | $0.07 | −$6.05 | — | $8.68 |
| 2018 | $1.03 | −$3.97 | $0.08 | −$5.92 | — | $11.97 |
| 2019 | $1.83 | −$7.12 | $0.44 | −$6.54 | — | $11.30 |
| 2020 | $4.45 | −$3.07 | $0.72 | −$2.89 | — | $17.28 |
| 2021 | $5.18 | −$6.70 | $1.08 | −$6.07 | — | $13.30 |
| 2022 | $5.20 | −$10.12 | $1.66 | −$7.10 | — | $5.01 |
| 2023 | $5.90 | −$8.26 | $0.60 | −$7.06 | — | $3.34 |
| 2024 | $6.19 | −$6.29 | $0.08 | −$4.65 | — | $2.76 |
| 2025 | $6.83 | −$5.83 | $0.06 | −$4.79 | — | −$0.83 |